modelH01AC06
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Tesamorelin | |
| ATC code: | H01AC06 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 9.4 | L |
| clearance: | 32.8 | L/h |
| other parameters in model implementation | ||
Tesamorelin is a synthetic peptide analogue of human growth hormone-releasing factor (GRF/ GHRH) used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to increase the secretion of endogenous growth hormone (GH). Tesamorelin is approved by the FDA for this indication.
Pharmacokinetics
Pharmacokinetics in healthy adult volunteers (both sexes, aged 18–55 years) after subcutaneous administration.
References
González-Sales, M, et al., & Tanguay, M (2015). Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics 54(3) 285–294. DOI:10.1007/s40262-014-0202-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/25358450
González-Sales, M, et al., & Tanguay, M (2015). Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. Journal of pharmacokinetics and pharmacodynamics 42(3) 287–299. DOI:10.1007/s10928-015-9416-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25895899
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)